Mesirow Institutional Investment Management Inc. Has $15.78 Million Stake in Enovis Co. (NYSE:ENOV)

Mesirow Institutional Investment Management Inc. boosted its holdings in Enovis Co. (NYSE:ENOV) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 359,674 shares of the company’s stock after purchasing an additional 1,072 shares during the quarter. Enovis comprises approximately 1.2% of Mesirow Institutional Investment Management Inc.’s investment portfolio, making the stock its 25th largest holding. Mesirow Institutional Investment Management Inc. owned about 0.63% of Enovis worth $15,782,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ENOV. FMR LLC raised its holdings in shares of Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares during the last quarter. Barclays PLC raised its stake in shares of Enovis by 16.1% in the third quarter. Barclays PLC now owns 368,488 shares of the company’s stock worth $15,864,000 after purchasing an additional 51,151 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Enovis by 9.5% in the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock valued at $39,678,000 after purchasing an additional 80,165 shares in the last quarter. Retirement Systems of Alabama boosted its position in shares of Enovis by 10.1% during the third quarter. Retirement Systems of Alabama now owns 67,846 shares of the company’s stock valued at $2,921,000 after buying an additional 6,239 shares during the last quarter. Finally, Confluence Investment Management LLC bought a new stake in Enovis during the fourth quarter worth $3,494,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

Shares of NYSE ENOV opened at $31.91 on Friday. The company has a market capitalization of $1.82 billion, a PE ratio of -14.57 and a beta of 1.86. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The stock’s 50 day moving average price is $37.53 and its 200-day moving average price is $42.17. Enovis Co. has a twelve month low of $29.32 and a twelve month high of $56.89.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. The firm had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, equities analysts anticipate that Enovis Co. will post 2.79 EPS for the current year.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of Enovis in a report on Wednesday, April 9th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.